Key result
An experimental protocol was developed in a monocrotaline-induced rat model of pulmonary arterial hypertension to comprehensively assess the response to pharmacologic treatments over 14 days.
Why the study?
Identifying new treatments for primary pulmonary arterial hypertension remains a critical unmet need lacking a definitive cure, requiring a rigorous protocol to comprehensively assess pharmacological responses.
Does pharmacologic treatment improve right ventricular systolic pressure in a rat model of monocrotaline-induced pulmonary arterial hypertension?
Does pharmacologic treatment improve right ventricular systolic pressure in a rat model of monocrotaline-induced pulmonary arterial hypertension?
This paper outlines a comprehensive, stepwise experimental protocol for evaluating new pharmacological treatments in a monocrotaline-induced rat model of pulmonary arterial hypertension.
Facilitates standardized 14-day pharmacologic testing in PAH rat models; extends preclinical methods but leaves open human translation.
The identification of new treatments for primary pulmonary arterial hypertension (PAH) is a critical unmet need since there is no a definitive cure for this disease yet. Due to the complexity of PAH, a wide set of methods are necessary to assess the response to a pharmacological intervention. Thus, a rigorous protocol is crucial when experimental studies are designed. In the present experimental protocol, a stepwise approach was followed in a monocrotaline-induced PAH model in the rat, moving from the dose finding study of treatment compounds to the recognition of the onset of disease manifestation, in order to identify when to start a curative treatment. A complete multidimensional evaluation of treatment effects represented the last step. The primary study endpoint was the change in right ventricular systolic pressure after 14 days of treatment; echocardiographic and biohumoral markers together with heart and pulmonary arterial morphometric parameters were considered as secondary efficacy and/or safety endpoints and for the evaluation of the biologic coherence in the different results.
No takes yet. Share an insight, caveat, or question.
Novelli et al. (2019) studied primary pulmonary arterial hypertension (PAH). pharmacologic treatments was evaluated on change in right ventricular systolic pressure after 14 days of treatment. An experimental protocol was developed in a monocrotaline-induced rat model of pulmonary arterial hypertension to comprehensively assess the response to pharmacologic treatments over 14 days.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: